Literature DB >> 22490684

Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.

Antonella Nai1, Alessia Pagani, Giacomo Mandelli, Maria Rosa Lidonnici, Laura Silvestri, Giuliana Ferrari, Clara Camaschella.   

Abstract

Inappropriately low expression of the key iron regulator hepcidin (HAMP) causes iron overload in untransfused patients affected by β-thalassemia intermedia and Hamp modulation provides improvement of the thalassemic phenotype of the Hbb(th3/+) mouse. HAMP expression is activated by iron through the bone morphogenetic protein (BMP)-son of mothers against decapentaplegic signaling pathway and inhibited by ineffective erythropoiesis through an unknown "erythroid regulator." The BMP pathway is inactivated by the serine protease TMPRSS6 that cleaves the BMP coreceptor hemojuvelin. Here, we show that homozygous loss of Tmprss6 in Hbb(th3/+) mice improves anemia and reduces ineffective erythropoiesis, splenomegaly, and iron loading. All these effects are mediated by Hamp up-regulation, which inhibits iron absorption and recycling. Because Hbb(th3/+) mice lacking Tmprss6 show residual ineffective erythropoiesis, our results indicate that Tmprss6 is essential for Hamp inhibition by the erythroid regulator. We also obtained partial correction of the phenotype in Tmprss6 haploinsufficient Hbb(th3/+) male but not female mice and showed that the observed sex difference reflects an unequal balance between iron and erythropoiesis-mediated Hamp regulation. Our study indicates that preventing iron overload improves β-thalassemia and strengthens the essential role of Tmprss6 for Hamp suppression, providing a proof of concept that Tmprss6 manipulation can offer a novel therapeutic option in this condition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22490684      PMCID: PMC3426375          DOI: 10.1182/blood-2012-01-401885

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.

Authors:  Orly Weizer-Stern; Konstantin Adamsky; Ninette Amariglio; Eliezer Rachmilewitz; Laura Breda; Stefano Rivella; Gideon Rechavi
Journal:  Am J Hematol       Date:  2006-07       Impact factor: 10.047

2.  Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

Authors:  Sara Gardenghi; Pedro Ramos; Maria Franca Marongiu; Luca Melchiori; Laura Breda; Ella Guy; Kristen Muirhead; Niva Rao; Cindy N Roy; Nancy C Andrews; Elizabeta Nemeth; Antonia Follenzi; Xiuli An; Narla Mohandas; Yelena Ginzburg; Eliezer A Rachmilewitz; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

3.  Effect of blood donation on iron stores as evaluated by serum ferritin.

Authors:  C A Finch; J D Cook; R F Labbe; M Culala
Journal:  Blood       Date:  1977-09       Impact factor: 22.113

4.  Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.

Authors:  B Modell; M Khan; M Darlison
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

5.  Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload.

Authors:  Vera Niederkofler; Rishard Salie; Silvia Arber
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

6.  The serine protease TMPRSS6 is required to sense iron deficiency.

Authors:  Xin Du; Ellen She; Terri Gelbart; Jaroslav Truksa; Pauline Lee; Yu Xia; Kevin Khovananth; Suzanne Mudd; Navjiwan Mann; Eva Marie Y Moresco; Ernest Beutler; Bruce Beutler
Journal:  Science       Date:  2008-05-01       Impact factor: 47.728

7.  Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia.

Authors:  Laura Silvestri; Flavia Guillem; Alessia Pagani; Antonella Nai; Claire Oudin; Muriel Silva; Fabienne Toutain; Caroline Kannengiesser; Carole Beaumont; Clara Camaschella; Bernard Grandchamp
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

Review 8.  Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.

Authors:  Ali Taher; Chaim Hershko; Maria Domenica Cappellini
Journal:  Br J Haematol       Date:  2009-08-13       Impact factor: 6.998

9.  Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia.

Authors:  Lucia De Franceschi; Filomena Daraio; Alida Filippini; Sonia Carturan; Eva Maria Muchitsch; Antonella Roetto; Clara Camaschella
Journal:  Haematologica       Date:  2006-10       Impact factor: 9.941

10.  Novel TMPRSS6 mutations associated with iron-refractory iron deficiency anemia (IRIDA).

Authors:  Luigia De Falco; Francesca Totaro; Antonella Nai; Alessia Pagani; Domenico Girelli; Laura Silvestri; Carmelo Piscopo; Natascia Campostrini; Carlo Dufour; Fahd Al Manjomi; Milen Minkov; Dennis G Van Vuurden; Aurora Feliu; Antonis Kattamis; Clara Camaschella; Achille Iolascon
Journal:  Hum Mutat       Date:  2010-05       Impact factor: 4.878

View more
  65 in total

Review 1.  Modulation of hepcidin to treat iron deregulation: potential clinical applications.

Authors:  Nicole L Blanchette; David H Manz; Frank M Torti; Suzy V Torti
Journal:  Expert Rev Hematol       Date:  2015-12-15       Impact factor: 2.929

2.  Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.

Authors:  Carla Casu; Mariateresa Pettinato; Alison Liu; Mariam Aghajan; Vania Lo Presti; Maria Rosa Lidonnici; Kevin A Munoz; Emir O'Hara; Violante Olivari; Simona Maria Di Modica; Sheri Booten; Shuling Guo; Garry Neil; Reem Miari; Nir Shapir; Inbal Zafir-Lavie; Hagit Domev; Giuliana Ferrari; Despina Sitara; Antonella Nai; Stefano Rivella
Journal:  Blood       Date:  2020-10-22       Impact factor: 22.113

3.  Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.

Authors:  Léon Kautz; Grace Jung; Xin Du; Victoria Gabayan; Justin Chapman; Marc Nasoff; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2015-08-14       Impact factor: 22.113

Review 4.  New strategies to target iron metabolism for the treatment of beta thalassemia.

Authors:  Paraskevi Rea Oikonomidou; Carla Casu; Stefano Rivella
Journal:  Ann N Y Acad Sci       Date:  2016-02-25       Impact factor: 5.691

Review 5.  Liver iron sensing and body iron homeostasis.

Authors:  Chia-Yu Wang; Jodie L Babitt
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

Review 6.  Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia.

Authors:  Stefano Rivella
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

Review 7.  Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Authors:  Paul J Schmidt; Mark D Fleming
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 8.  The pathophysiology and pharmacology of hepcidin.

Authors:  Piotr Ruchala; Elizabeta Nemeth
Journal:  Trends Pharmacol Sci       Date:  2014-02-17       Impact factor: 14.819

Review 9.  Oxidative Stress in β-Thalassemia.

Authors:  Eitan Fibach; Mutaz Dana
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

10.  An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.

Authors:  Paul J Schmidt; Iva Toudjarska; Anoop K Sendamarai; Tim Racie; Stuart Milstein; Brian R Bettencourt; Julia Hettinger; David Bumcrot; Mark D Fleming
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.